|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
IMMUNOBIOLOGY
From the Third Department of Internal Medicine and the
Center for Chronic Viral Diseases, Faculty of Medicine, Kagoshima
University, and the Department of Internal Medicine, Kagoshima City
Hospital, Kagoshima, Japan.
Although Tax protein is the main target of cytotoxic T lymphocyte
(CTL) on human T-cell lymphotropic virus type I (HTLV-I)-infected cells, and Tax peptide 11 through 19 binding to HLA-A*02 has been shown
to elicit a strong CTL response, there are patients with adult T-cell
leukemia (ATL) bearing HLA-A*02. To explore whether there is genetic
variation in HTLV-I tax that can escape CTL recognition during the development of ATL, the HTLV-I tax gene was
sequenced in 55 patients with ATL, 61 patients with HTLV-I-associated
myelopathy/tropical spastic paraparesis (HAM/TSP), and 62 healthy
carriers, and it was correlated with the presence of HLA-A*02. First, a
premature stop codon in the 5' half of the tax gene that
looses transactivation activity on the viral enhancer was observed in 3 patients with acute and 1 patient with chronic ATL. This stop codon was
revealed to emerge after the viral transmission to the patient from
sequence analysis in family members with ATL. Second, amino acid change in Tax peptide 11-19 was observed in 3 patients with ATL. CTL assays
demonstrated that this altered Tax 11-19 peptide, observed in ATL
patients with HLA-A*02, was not recognized by Tax 11-19-specific CTL.
Two patients with ATL had large deletions in tax by
sequencing, and 5 patients with ATL had deletions in HTLV-I by Southern
blotting. These findings suggest that at some stage of ATL development, HTLV-I-infected cells that can escape the host immune system are selected and have a chance to accumulate genetic alterations for further malignant transformation, leading to acute ATL.
(Blood. 2001;97:987-993) Human T-cell lymphotropic virus type I (HTLV-I) is
the etiologic agent of adult T-cell leukemia (ATL)1,2 and
HTLV-I-associated myelopathy/tropical spastic paraparesis
(HAM/TSP).3,4 Regarding the mechanism of ATL development,
HTLV-I Tax protein has been mainly studied as a key regulator for
immortalization, transformation, and oncogenesis of the HTLV-I
infected-lymphocytes through its interaction with many cellular
proteins. For example, Tax binds to CBP/p300 and determines the
accessibility of CBP/p300 to protein complexes on specific DNA
elements,5 resulting in Tax-mediated transactivation of viral genes6 and growth
factors,7 or transrepression of p18,8 DNA
polymerase Tax plays a role as an immunodominant target antigen for cytotoxic T
lymphocyte (CTL) response to HTLV-I.12,13 Although the
mechanisms by which HTLV-I causes HTLV-I-related diseases are not
fully elucidated, the HLA subtype has been shown to influence the
outcome of HTLV-I infection. In acute and lymphoma-type ATL, high
frequencies of HLA-A26 have been reported.14 On the other hand, HLA-A*02 has been demonstrated to reduce the risk for
HAM/TSP.15 It has been suggested that HLA-A*02 has high
binding affinity to the Tax 11-19 peptide and thus induces a strong CTL
response to HTLV-I-infected cells, resulting in low provirus load and
providing protection from HAM/TSP. Despite such a high CTL response to
HTLV-I and a low provirus load in HLA-A*02-positive HTLV-I carriers, some ATL patients have HLA-A*02. It is of interest to know whether an
escape mutant exists in the core epitope of Tax in patients with ATL.
It is well known that Tax is rarely detected in fresh peripheral ATL
cells,16 and the expression level of tax/rex
mRNA in each HTLV-I-infected cell is far lower in ATL than in HAM/TSP and in healthy carriers (HCs).17 One possible explanation
is that immortalized cells, no longer requiring Tax expression, are selected during the development of ATL. Tax promotes the proliferation of HTLV-I-infected cells in many ways by influencing host gene expression in the early stages of leukemogenesis. However, Tax can also
reduce cellular proliferation of infected cells because Tax-expressing
cells will be rejected by the host immune response. There may be a
stage at which a balance of competition develops between the advantages
and disadvantages of Tax for proliferation during leukemogenesis.
At such a stage, it is possible that immortalized cells that
elicit weaker CTL responses are selected during the development of ATL.
In this study, we sought nucleotide substitutions in the tax
gene that may enable escape from the CTL response among
patients with ATL. Here we report a stop codon in the 5' half of the
tax gene that was selected during the development of ATL and
an amino acid change in the epitope that leads to evasion of the immune response in HLA-A*02-positive ATL patients. These findings strongly suggest that viral escape from the host immune system also plays an
important role in the development of ATL.
Study population
Sequencing of HTLV-I tax gene
Cloning of tax gene In one healthy carrier, a mixture of 2 consensus sequences was suggested by direct sequencing because of 2 peaks at one nucleotide position. The amplified DNA product of tax gene was subcloned into pCR-Blunt II-TOPO cloning vector (Invitrogen, CA), and the subclones were sequenced as described above.HLA-A*02 typing PCR sequence-specific primer reactions were performed to detect HLA-A*02 as previously described22 in all samples.Recognition of wild-type and mutated Tax peptides by a Tax 11-19-specific CTL clone Wild-type ( HTLV-I Tax 11-19 peptide; LLFGYPVYV) and the mutated HTLV-I Tax peptide observed in patients with ATL (LLFRYPVYV) were synthesized and purified by high-performance liquid chromatography (Kurabo, Osaka, Japan). Influenza virus M1 peptide (GILGFVFTL) was used as a control peptide for binding to HLA-A2.23 A Tax 11-19-specific CTL clone restricted with HLA-A2 (N1216) was stimulated with 5 × 106 HLA-A2-matched allogenic peripheral blood mononuclear cells prepulsed with 1 mM wild-type Tax 11-19 peptides and 30 U/mL IL-2, as previously described.24 The CTL clone was used 6 days after restimulation. The CTL assay was conducted using Europium (Aldrich Chemical, Milwaukee, WI), as described.25 HLA-A2-transfected Hmy2.C1R (Hmy-A2) cells served as targets.26 Hmy-A2 cells were labeled with 50 µM fluorescence-enhancing ligand, bis (acetoxymethyl) 2,2':6',2''-terpyridine-6,6''-dicarboxylase (BATD; Wallac Instruments, Turku, Finland), incubated at 37°C for 20 minutes. After they were washed 3 times with RPMI-1640 with 5% FCS, 2.8 mM L-glutamine, 40 U/mL penicillin, 40 µg/mL streptomycin, and 125 µM sulfinpyrazone (Sigma, Tokyo, Japan), Hmy-A2 cells were unpulsed or pulsed with wild-type Tax peptide (Tax 11-19; LLFGYPVYV), mutant Tax peptide (G4R; LLFRYPVYV), or M1 peptide (GILGFVFTL) at a final concentration of 1 µM and incubated at 37°C for 30 minutes. After cells were washed, 2000 target cells were transferred to each well in a 96-well round-bottom plate. Effector cells were transferred to the well at a effector-target ratios of 10:1, 3:1, and 1:1 and were incubated at 37°C for 4 hours. After incubation, 40 µL supernatant was transferred to wells containing 160 µL of 50 µM Europium solution (Aldrich Chemical). After 5-minute mixing at room temperature, the fluorescence intensity of the chelates formed by Europium and fluorescence-enhancing ligand was measured by a fluorometer (1420ARVOsx; Wallac). Maximal release was produced by the incubation of target cells in 1% Triton X-100, and spontaneous release was produced by incubation in medium alone. The specific lysis was calculated with the following formula: [(experimental release spontaneous
release)/(maximum releasespontaneous release)] × 100.
Southern blot analysis of HTLV-I Southern blot analysis of HTLV-I was performed in all patients with ATL. High-molecular-weight DNA was extracted by a standard method using phenol extraction. Ten micrograms genomic DNA was digested with PstI, separated on a 1% agarose gel, and transferred to a nylon membrane. Probes used in hybridization were a total sequence of HTLV-I and HTLV-I long-terminal repeat (LTR). Total sequence of HTLV-I DNA probe was labeled with -32P-dCTP by random priming.
Blots were hybridized at 65°C for 12 hours in a mixture containing
4 × SSC (1 × SSC; 0.15 M NaCl, 0.015 M sodium citrate), 50µg
sonicated, and denatured salmon sperm DNA. Then they were washed in
0.1% sodium dodecyl sulfate and 1 × SSC at 65°C for 30 minutes
and autoradiographed. The same filters were rehybridized with the
32P-labeled HTLV-I LTR probe.
DDBJ accession numbers Accession numbers of tax sequence in patients with ATL were successively from AB036372 through AB36383 and from AB045399 through AB045441. Accession numbers of tax sequence in patients with HAM were successively from AB036355 through AB036371 and from AB045442 through AB045185. Accession numbers of tax sequence in HCs were successively from AB036384 through AB036395 and from AB045486 through AB045559. Accession numbers of the tax sequence of family members of the patients in Table 3 are AB045632 for the son of HAM 9, AB045633 for the son of HAM 10, AB045634 for the wife of HAM 19, AB045635 for a sister of HAM 24, AB045636 for a sister of HAM 34 (1) AB045637 for a sister of HAM 34 (2) AB045638 for the husband of HAM 39, AB045639 for the mother of ATL 36, and AB045640 for the sister of ATL 36. Accession numbers of the tax sequence at different occasions in Table 4 are AB045641 for HAM 5 at August 18, 1997, AB045642 for HAM 15 on April 16, 1999, AB045643 for HAM 49 on April 7, 1997, and AB045644 for HAM 61 on January 22, 1998.
Sequence variation in the HTLV-I tax gene Initially, we analyzed HTLV-I tax gene by sequencing in 55 patients with ATL, 61 patients with HAM/TSP, and 62 HCs. Four specific nucleotides (nucleotide positions at 7897, 7959, 8208, 8344) discriminate between 2 tax subgroups in Kagoshima, Japan.21 Besides these specific nucleotide alterations, several nucleotide substitutions occurred in many patients and carriers. In Figure 1, we summarized the observed nucleotide alterations, Tax and Rex amino acid changes, that lay outside the 4 specific nucleotide positions that define tax subgroups. Tax amino acids in the 5' half and Rex amino acids tended to be more conserved in patients with HAM/TSP (Figure 1, Table 1).
On the other hand, 2 kinds of tax nucleotide substitutions
were specifically observed in patients with ATL. One of these
substitutions was a premature stop codon in the 5' half of the
tax gene (Table 2). A
nucleotide substitution at 7464 from G to A, which creates a TAG stop
codon, was observed in 3 patients with acute ATL and 1 patient with
chronic ATL.
A second tax nucleotide substitution frequently observed in
the consensus tax sequence of patients with ATL was at
nucleotide position 7337 from A to G (Table 2). Three patients with
acute ATL had this substitution. Direct sequence suggested that there was a mixture of the wild-type and this altered tax in one
healthy carrier (HC 34). Sequencing of the subcloned tax PCR
product confirmed this mixture in HC 34 (Figure
2). There was also a nucleotide substitution at position 7464 that created a stop codon in a single subclone in HC 34 (Figure 2).
Transmission analysis of HTLV-I with nucleotide alterations To examine whether HTLV-I with these tax nucleotide substitutions is transmittable, we sequenced the tax gene in 7 healthy HTLV-I carriers who are family members of 6 HAM/TSP patients with tax nucleotide substitutions. Each family member had completely the same tax gene, with substitutions that were observed in the HAM/TSP patients in their family (Table 3). For example, a son of HAM 9 had an identical tax gene sequence with a substitution at nucleotide position 7953, which suggest this HTLV-I was transmitted from HAM 9. Two sisters of HAM 34 had an identical tax gene sequence with substitutions at nucleotide position 7496, which suggest this HTLV-I was transmitted from their mother and was only observed in each family (Table 3). We also sequenced the tax gene at different time points in some of the HAM/TSP patients; however, in each patient these nucleotide substitutions were the same over time (Table 4).
We sequenced the HTLV-I tax gene in the sister and mother of ATL 36, the patient who had a substitution at 7464 that created a stop codon and who had 2 additional nucleotide substitutions (at positions 7743 and 8294). The sequences of the tax gene were identical in the patient, his sister, and their mother, except that a stop codon was detected only in the patient (Table 3). Presence of HLA-A*02 The nucleotide substitution at position 7337 from A to G caused an amino acid change from glycine to arginine at amino acid position 14 of the Tax protein. This substitution is responsible for an alteration in the immunodominant epitope of Tax 11-19 in HLA-A*02 patients; therefore, we analyzed the presence of HLA-A*02. The frequency of HLA-A*02 was 27 of 62 (43.5%) in HCs and 16 of 61 (26.2%) in patients with HAM/TSP, and this difference was significant (P = .034; 1-tailed Fisher exact test) (Table 2). The frequency of HLA-A*02 in patients with ATL was 21 of 55 (38.2%) and did not differ significantly from that in HCs or patients with HAM/TSP. Among the 4 ATL patients with a premature stop codon at 7464, one was positive for HLA-A*02. Among the 3 ATL patients with amino acid alteration at position 14 of Tax, 2 were HLA-A*02 positive and one was HLA-A*02 negative (Table 2). HC 34, who had a mixture of wild-type and variant Tax at amino acid position 14 (nucleotide position at 7337), was positive for HLA-A*02 (Table 2).Recognition of wild-type and altered Tax peptides by a Tax 11-19-specific CTL clone In contrast to the recognition of the wild-type Tax peptide 11-19 (LLFGYPVYV) by the Tax 11-19-specific CTL clone, the altered Tax peptide G4R (amino acid change at position 14 of Tax protein) (LLFRYPVYV) was not recognized (Figure 3).
Southern blot analysis of HTLV-I Southern blot analysis of the HTLV-I genome digested with PstI using whole HTLV-I as a probe revealed monoclonal proliferation of HTLV-I-infected cells in all patients with ATL. A typical ATL pattern of Southern blot analysis is shown in Figure 4, lane 1. Five patients with ATL had deletion of the internal band (Figure 4; lanes 2-6). These patients had neither a stop codon nor an amino acid change in Tax 11-19. Sequence analysis of the tax gene revealed 2 other ATL patients with deletions. One had a tax gene deletion from nucleotide position at 7392 through 8317 and the other had a deletion from nucleotide position 7388 through 8277. These patients did not have any amino acid change in Tax peptide 11-19.
The purpose of this study was to test the hypothesis that escape of HTLV-I-infected cells from CTL recognition is involved during the development of ATL. When we sequenced the tax gene in 55 patients with ATL, 62 patients with HAM/TSP, and 61 HCs, we found a subgroup with the tax gene defined by 4 specific nucleotide substitutions (nucleotide positions at 7897, 7959, 8208, 8344). The tax sequence subgroups were strongly associated with the subgroups based on the LTR sequence.21 Because these 4 specific nucleotide substitutions are not mutations but rather subgroup-specific nucleotide alterations, we sought tax nucleotide substitutions other than these 4 specific nucleotides that are specifically observed in patients with ATL. Peaks at nucleotide positions 7720 and 8297 in patients with HAM/TSP were found in a subcluster of the tax subgroup with 4 specific nucleotide alterations, and this sequence was not disease specific.21 Some nucleotide changes seemed to have significance and to be specific for ATL. A nucleotide change from G to A at position 7464 created a premature stop codon in 4 patients with ATL (3 acute and 1 chronic ATL). These stop codons were observed only in ATL and not in HAM/TSP or HCs as a consensus sequence of individual cases (Table 2). Because Tax with this premature stop codon in the 5' half had been shown to have no function,27 we were interested in finding out whether HTLV-I with this stop codon in tax is transmittable or whether such a mutation emerged after HTLV-I was transmitted to the patient. When we analyzed the transmission of HTLV-I with nucleotide alterations in tax, tax nucleotide substitutions in the HC family members of patients with HAM/TSP were identical to the tax nucleotide substitutions in the HAM/TSP patients in each family (Table 3). Moreover, tax nucleotide substitutions were the same in each person on each occasion (Table 4). These findings suggest that a new consensus sequence of tax did not emerge in HAM/TSP patients after the HTLV-I transmission to the patients. On the other hand, when we analyzed the tax sequence of family members (sister and mother) of one patient with ATL (ATL 36) who had 2 nucleotide substitutions (at positions 7743 and 8294) in addition to the substitution at 7464, which created a stop codon, only the 2 nucleotide substitutions were observed. The stop codon was not detected in the family members (Table 3). This result demonstrates that HTLV-I with these 2 nucleotide substitutions (at position 7743 and 8294) was transmitted from the mother to ATL 36 and to his sister, but the stop codon emerged after the viral transmission to ATL 36. One may argue that this mutation emerged as a result of genetic instability after the malignant transformation to acute ATL. However, this stop codon was observed not only in acute ATL but also in one chronic ATL. In addition, we have previously reported frequent mutations in the pX region of HTLV-I as a single subclone in HTLV-I-infected persons.28 In this earlier paper,28 nucleotide positions 7460 through 8420 were sequenced. There was no stop codon in the consensus sequence of the individual patients, but there were tax subclones with mutations at nucleotide 7464, which created a stop codon as a single subclone in 3 of 5 patients with HAM/TSP and 1 of 2 HCs. There was also a nucleotide substitution at position 7464 that created a stop codon as a single subclone in HC 34 (Figure 2). These findings suggest that a nucleotide position at 7464 is a hot spot of mutation, and this mutation is unlikely to have been caused by the genetic instability in malignantly transformed ATL cells. Because truncated Tax in the 5' half region loses its function,27 HTLV-I itself cannot be transactivated by the Tax with premature stop codon, and HTLV-I associated antigens will not be expressed. Such HTLV-I-infected cells will lose their advantage in cell proliferation given by the wild-type Tax in transactivation activity but will gain advantage in immune response because those cells that do not express HTLV-I-related antigens will not be rejected by the CTL. If this stop codon occurs after the immortalization of HTLV-I-infected cells, such cells will not be rejected by the HTLV-I-specific CTL but will have chance to accumulate genetic alterations for further malignant transformation and may finally develop into acute ATL. The second peak of nucleotide alteration specifically observed in ATL
was in the Tax core epitope (amino acid positions 11-19) for
HLA-A*0212 in 3 patients with ATL. In these 3 patients, Tax
amino acid position 14 was altered from glycine to arginine because of
the nucleotide alteration at position 7337. Two of them were HLA-A*02
positive, and one was HLA-A*02 negative (Table 2). We examined whether
the altered Tax peptide (amino acid change at position 14 of Tax
protein) (LLFRYPVYV) can be recognized by the Tax 11-19-specific CTL
clone. In contrast to the recognition of the wild-type Tax peptide
(LLFGYPVYV), altered Tax peptide G4R (LLFRYPVYV) was not recognized
(Figure 3). This core epitope mutation was not present as a consensus
sequence in patients with HAM/TSP or in HCs. We could not examine the
HTLV-I carriers in the family members of ATL patients with this Tax
alteration and, therefore, could not identify whether this alteration
emerged after the HTLV-I transmission to the patient or whether this
altered HTLV-I is itself transmittable. However, one healthy carrier
(HC 34) had a mixture of the wild-type and this altered tax.
HC 34 was positive for HLA-A*02. Sequencing of the subcloned
tax PCR product in HC 34 revealed that there were variants
of both wild-type and altered tax at nucleotide position
7337 (Figure 2). Because variants are supposed to emerge by viral
replication, HTLV-I with this nucleotide alteration at 7337 must have
been expressed in the patient. There are several possibilities. One
possibility is that HTLV-I with the alteration at 7337 emerged after
viral transmission to the patient but still has impaired function. In this case, although transactivation activity is lower than the wild-type Tax, HTLV-I and the alteration in the core epitope for HLA-A*02 were selected by the CTL. The disadvantage of the altered Tax
in proliferation and the advantage of the ability to escape from the
CTL may make a mixture of both clones in HC 34, who is positive for
HLA-A*02. The second possibility is that HTLV-I, with the alteration at
7337, naturally exists with function and is transmittable, and both
wild-type and altered clones are infected in different cells in same
person. The third possibility is that though this mutation emerged
after the viral transmission to the patient and does not have
transactivating activity, wild-type HTLV-I is doubly infected in one
cell. In this case, both HTLV-I can be expressed by the wild-type Tax
in a cell, and variants can be observed for the both clones. We could
not distinguish these possibilities from our current data. One report
of this tax nucleotide variation at 7337 In addition to the immune escape from CTL as a mechanism for ATL development, frequent deletion of cyclin-dependent kinase inhibitor genes (p16INK4A and p15INK4B) has been reported in acute ATL.30 And it has been reported that chronic ATL, with deletions in these genes, rapidly progresses to acute ATL.30 These findings suggest that although viral escape from CTL recognition plays an important role in the development of ATL, genetic changes including cyclin-dependent kinase inhibitor genes are still required for further malignant transformation in the development of acute ATL. In conclusion, we speculate the mechanism of ATL development as follows. First, Tax plays an important role as a key regulator for proliferation and immortalization of the HTLV-I-infected lymphocytes through its interaction with cellular proteins in the early stages. Second, HTLV-I-infected cells not recognized by the CTL for HTLV-I are selected after immortalization at least in some cases. Finally, additional genetic changes for malignant transformation are accumulated and result in acute ATL.
We thank Ms. T. Muramoto and Ms. Y. Nishino (Third Department of Internal Medicine, Kagoshima University, Japan) for their excellent technical assistance; we also thank Professor Charles R. M. Bangham (Immunology Department, Imperial College School of Medicine at St. Mary's, United Kingdom) for critical reading of the manuscript.
Submitted July 20, 2000; accepted October 3, 2000.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Yoshitaka Furukawa, Third Department of Internal Medicine, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan; e-mail: furukawy{at}m2.kufm.kagoshima-u.ac.jp.
1.
Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC.
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.
Proc Natl Acad Sci U S A.
1980;77:7415-7419
2.
Yoshida M, Miyoshi I, Hinuma Y.
Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease.
Proc Natl Acad Sci U S A.
1982;79:2031-2035 3. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 1985;2:407-410[CrossRef][Medline] [Order article via Infotrieve]. 4. Osame M, Usuku K, Izumo S, et al. HTLV-I-associated myelopathy, a new clinical entity. Lancet. 1985;1:1031-1032[CrossRef]. 5. Suzuki T, Uchida Toita M, Yoshida M. Tax protein of HTLV-1 inhibits CBP/p300-mediated transcription by interfering with recruitment of CBP/p300 onto DNA element of E-box or p53 binding site. Oncogene. 1999;18:4137-4143[CrossRef][Medline] [Order article via Infotrieve]. 6. Giebler HA, Loring JE, van Orden K, et al. Anchoring of CREB binding protein to the human T-cell leukemia virus type 1 promoter: a molecular mechanism of Tax transactivation. Mol Cell Biol. 1997;17:5156-5164[Abstract].
7.
Siekevitz M, Feinberg MB, Holbrook N, Wong Staal F, Greene WC.
Activation of interleukin 2 and interleukin 2 receptor (Tac) promoter expression by the trans-activator (tat) gene product of human T-cell leukemia virus, type I.
Proc Natl Acad Sci U S A.
1987;84:5389-5393 8. Suzuki T, Narita T, Uchida Toita M, Yoshida M. Down-regulation of the INK4 family of cyclin-dependent kinase inhibitors by tax protein of HTLV-1 through two distinct mechanisms. Virology. 1999;259:384-391[CrossRef][Medline] [Order article via Infotrieve]. 9. Brauweiler A, Garrus JE, Reed JC, Nyborg JK. Repression of bax gene expression by the HTLV-1 Tax protein: implications for suppression of apoptosis in virally infected cells. Virology. 1997;231:135-140[CrossRef][Medline] [Order article via Infotrieve]. 10. Suzuki T, Kitao S, Matsushime H, Yoshida M. HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16INK4A and counteracts its inhibitory activity towards CDK4. EMBO J. 1996;15:1607-1614[Medline] [Order article via Infotrieve]. 11. Suzuki T, Ohsugi Y, Uchida Toita M, Akiyama T, Yoshida M. Tax oncoprotein of HTLV-1 binds to the human homologue of Drosophila discs large tumor suppressor protein, hDLG, and perturbs its function in cell growth control. Oncogene. 1999;18:5967-5977[CrossRef][Medline] [Order article via Infotrieve].
12.
Kannagi M, Shida H, Igarashi H, et al.
Target epitope in the Tax protein of human T-cell leukemia virus type I recognized by class I major histocompatibility complex-restricted cytotoxic T cells.
J Virol.
1992;66:2928-2933
13.
Pique C, Connan F, Levilain JP, Choppin J, Dokhelar MC.
Among all human T-cell leukemia virus type 1 proteins, tax, polymerase, and envelope proteins are predicted as preferential targets for the HLA-A2-restricted cytotoxic T-cell response.
J Virol.
1996;70:4919-4926 14. Usuku K, Sonoda S, Osame M, et al. HLA haplotype-linked high immune responsiveness against HTLV-I in HTLV-I-associated myelopathy: comparison with adult T-cell leukemia/lymphoma. Ann Neurol. 1988;23(suppl):S143-S150.
15.
Jeffery KJ, Usuku K, Hall SE, et al.
HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy.
Proc Natl Acad Sci U S A.
1999;96:3848-3853
16.
Yoshida M, Seiki M, Yamaguchi K, Takatsuki K.
Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease.
Proc Natl Acad Sci U S A.
1984;81:2534-2537
17.
Furukawa Y, Osame M, Kubota R, Tara M, Yoshida M.
Human T-cell leukemia virus type-1 (HTLV-1) Tax is expressed at the same level in infected cells of HTLV-1-associated myelopathy or tropical spastic paraparesis patients as in asymptomatic carriers but at a lower level in adult T-cell leukemia cells.
Blood.
1995;85:1865-1870 18. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79:428-437[Medline] [Order article via Infotrieve]. 19. Osame M. HTLV. In: Blattner E, ed. Human Retrovirology. New York: Raven Press; 1990:191-197.
20.
Seiki M, Hattori S, Hirayama Y, Yoshida M.
Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA.
Proc Natl Acad Sci U S A.
1983;80:3618-3622 21. Furukawa Y, Yamashita M, Usuku K, Izumo S, Nakagawa M, Osame M. Phylogenetic subgroups of HTLV-I in tax gene and their association with different risk to HTLV-I-associated myelopathy/ tropical spastic paraparesis. J Infect Dis. In press. 22. Bunce M, O'Neill CM, Barnardo MC, et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 and DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens. 1995;46:355-367[Medline] [Order article via Infotrieve]. 23. Utz U, Koenig S, Coligan JE, Biddison WE. Presentation of three different viral peptides, HTLV-1 Tax, HCMV gB, and influenza virus M1, is determined by common structural features of the HLA-A2.1 molecule. J Immunol. 1992;149:214-221[Abstract].
24.
Kubota R, Soldan S, Martin R, Jacobson S.
An altered peptide ligand antagonizes antigen-specific T cells of patients with human T lymphotropic virus type I-associated neurological disease.
J Immunol.
2000;164:5192-5198 25. Blomberg K, Hautala R, Lovgren J, Mukkala VM, Lindqvist C, Akerman K. Time-resolved fluorometric assay for natural killer activity using target cells labeled with a fluorescence enhancing ligand. J Immunol Methods. 1996;193:199-206[CrossRef][Medline] [Order article via Infotrieve]. 26. Storkus WJ, Howell DN, Salter RD, Dawson JR, Cresswell P. NK susceptibility varies inversely with target cell class I HLA antigen expression. J Immunol. 1987;138:1657-1659[Medline] [Order article via Infotrieve]. 27. Seiki M, Inoue J, Takeda T, Yoshida M. Direct evidence that p40x of human T-cell leukemia virus type I is a trans-acting transcriptional activator. EMBO J. 1986;5:561-565[Medline] [Order article via Infotrieve]. 28. Saito M, Furukawa Y, Kubota R, et al. Frequent mutation in pX region of HTLV-1 is observed in HAM/TSP patients, but is not specifically associated with the central nervous system lesions. J Neurovirol. 1995;1:286-294[Medline] [Order article via Infotrieve]. 29. Niewiesk S, Daenke S, Parker CE, et al. Naturally occurring variants of human T-cell leukemia virus type I Tax protein impair its recognition by cytotoxic T lymphocytes and the transactivation function of Tax. J Virol. 1995;69:2649-2653[Abstract].
30.
Hatta Y, Hirama T, Miller CW, Yamada Y, Tomonaga M, Koeffler HP.
Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia.
Blood.
1995;85:2699-2704
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  R.-i. Fukuda, K. Tsuchiya, K. Suzuki, K. Itoh, J. Fujita, A. Utsunomiya, and T. Tsuji Human T-cell Leukemia Virus Type I Tax Down-regulates the Expression of Phosphatidylinositol 3,4,5-Trisphosphate Inositol Phosphatases via the NF-{kappa}B Pathway J. Biol. Chem., January 30, 2009; 284(5): 2680 - 2689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Arnold, B. Zimmerman, M. Li, M. D. Lairmore, and P. L. Green Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T-lymphocyte proliferation Blood, November 1, 2008; 112(9): 3788 - 3797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Miyazaki, J.-I. Yasunaga, Y. Taniguchi, S. Tamiya, T. Nakahata, and M. Matsuoka Preferential Selection of Human T-Cell Leukemia Virus Type 1 Provirus Lacking the 5' Long Terminal Repeat during Oncogenesis J. Virol., June 1, 2007; 81(11): 5714 - 5723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Murata, T. Hayashibara, K. Sugahara, A. Uemura, T. Yamaguchi, H. Harasawa, H. Hasegawa, K. Tsuruda, T. Okazaki, T. Koji, et al. A Novel Alternative Splicing Isoform of Human T-Cell Leukemia Virus Type 1 bZIP Factor (HBZ-SI) Targets Distinct Subnuclear Localization J. Virol., March 1, 2006; 80(5): 2495 - 2505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Satou, J.-i. Yasunaga, M. Yoshida, and M. Matsuoka HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells PNAS, January 17, 2006; 103(3): 720 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Watanabe, T. Ohsugi, M. Shoda, T. Ishida, S. Aizawa, M. Maruyama-Nagai, A. Utsunomiya, S. Koga, Y. Yamada, S. Kamihira, et al. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-{kappa}B, as a strategy for chemoprevention and therapy of adult T-cell leukemia Blood, October 1, 2005; 106(7): 2462 - 2471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Doi, X. Wu, Y. Taniguchi, J.-i. Yasunaga, Y. Satou, A. Okayama, K. Nosaka, and M. Matsuoka Preferential selection of human T-cell leukemia virus type I provirus integration sites in leukemic versus carrier states Blood, August 1, 2005; 106(3): 1048 - 1053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Matsuoka and K.-T. Jeang Human T-Cell Leukemia Virus Type I at Age 25: A Progress Report Cancer Res., June 1, 2005; 65(11): 4467 - 4470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Moules, C. Pomier, D. Sibon, A.-S. Gabet, M. Reichert, P. Kerkhofs, L. Willems, F. Mortreux, and E. Wattel Fate of Premalignant Clones during the Asymptomatic Phase Preceding Lymphoid Malignancy Cancer Res., February 15, 2005; 65(4): 1234 - 1243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Yoshizuka, R. Moriuchi, T. Mori, K. Yamada, S. Hasegawa, T. Maeda, T. Shimada, Y. Yamada, S. Kamihira, M. Tomonaga, et al. An Alternative Transcript Derived from the Trio Locus Encodes a Guanosine Nucleotide Exchange Factor with Mouse Cell-transforming Potential J. Biol. Chem., October 15, 2004; 279(42): 43998 - 44004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-i. Yasunaga, Y. Taniguchi, K. Nosaka, M. Yoshida, Y. Satou, T. Sakai, H. Mitsuya, and M. Matsuoka Identification of Aberrantly Methylated Genes in Association with Adult T-Cell Leukemia Cancer Res., September 1, 2004; 64(17): 6002 - 6009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mori, T. Matsuda, M. Tadano, T. Kinjo, Y. Yamada, K. Tsukasaki, S. Ikeda, Y. Yamasaki, Y. Tanaka, T. Ohta, et al. Apoptosis Induced by the Histone Deacetylase Inhibitor FR901228 in Human T-Cell Leukemia Virus Type 1-Infected T-Cell Lines and Primary Adult T-Cell Leukemia Cells J. Virol., May 1, 2004; 78(9): 4582 - 4590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Suzuki and M. Nei False-Positive Selection Identified by ML-Based Methods: Examples from the Sig1 Gene of the Diatom Thalassiosira weissflogii and the tax Gene of a Human T-cell Lymphotropic Virus Mol. Biol. Evol., May 1, 2004; 21(5): 914 - 921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nomura, T. Ohashi, K. Nishikawa, H. Nishitsuji, K. Kurihara, A. Hasegawa, R. A. Furuta, J.-i. Fujisawa, Y. Tanaka, S. Hanabuchi, et al. Repression of Tax Expression Is Associated both with Resistance of Human T-Cell Leukemia Virus Type 1-Infected T Cells to Killing by Tax-Specific Cytotoxic T Lymphocytes and with Impaired Tumorigenicity in a Rat Model J. Virol., April 15, 2004; 78(8): 3827 - 3836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yoshida, K. Nosaka, J.-i. Yasunaga, I. Nishikata, K. Morishita, and M. Matsuoka Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cells Blood, April 1, 2004; 103(7): 2753 - 2760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kubota, Y. Furukawa, S. Izumo, K. Usuku, and M. Osame Degenerate specificity of HTLV-1-specific CD8+ T cells during viral replication in patients with HTLV-1-associated myelopathy (HAM/TSP) Blood, April 15, 2003; 101(8): 3074 - 3081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E. McClelland, D. J. Penn, and W. K. Potts Major Histocompatibility Complex Heterozygote Superiority during Coinfection Infect. Immun., April 1, 2003; 71(4): 2079 - 2086. [Abstract] [Full Text]
|
|
|
|
|
|
S. Gottschalk, O. L. Edwards, U. Sili, M. H. Huls, T. Goltsova, A. R. Davis, H. E. Heslop, and C. M. Rooney Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies Blood, March 1, 2003; 101(5): 1905 - 1912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mori, Y. Yamada, S. Ikeda, Y. Yamasaki, K. Tsukasaki, Y. Tanaka, M. Tomonaga, N. Yamamoto, and M. Fujii Bay 11-7082 inhibits transcription factor NF-kappa B and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells Blood, August 13, 2002; 100(5): 1828 - 1834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Koiwa, A. Hamano-Usami, T. Ishida, A. Okayama, K. Yamaguchi, S. Kamihira, and T. Watanabe 5'-Long Terminal Repeat-Selective CpG Methylation of Latent Human T-Cell Leukemia Virus Type 1 Provirus In Vitro and In Vivo J. Virol., August 12, 2002; 76(18): 9389 - 9397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ohashi, S. Hanabuchi, R. Suzuki, H. Kato, T. Masuda, and M. Kannagi Correlation of Major Histocompatibility Complex Class I Downregulation with Resistance of Human T-Cell Leukemia Virus Type 1-Infected T Cells to Cytotoxic T-Lymphocyte Killing in a Rat Model J. Virol., June 14, 2002; 76(14): 7010 - 7019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Furuta, K. Sugiura, S. Kawakita, T. Inada, S. Ikehara, T. Matsuda, and J.-i. Fujisawa Mouse Model for the Equilibration Interaction between the Host Immune System and Human T-Cell Leukemia Virus Type 1 Gene Expression J. Virol., February 22, 2002; 76(6): 2703 - 2713. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
, and bax gene.
7293) and PXI3
), wild-type Tax peptide 11-19 (LLFGYPVYV). G4R (
),
altered Tax peptide at position 4 from glycine to arginine (LLFRYPVYV).
M1 (
), control influenza virus peptide (GILGFVFTL) known to
bind HLA-A2.
)PstI site. Lane 1: Typical
patient with ATL showing 3 major internal bands (2.5 kb, 1.8 kb, 1.2 kb) with additional 2 viral-cellular junction bands (arrowheads). Lanes
2-5: Patients with ATL with deletion of internal bands, suggesting wide
deletion in the HTLV-I virus (refer to the restriction map
above).